New research indicates that people who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who stop conventional diet and exercise regimens.
Published data in a major medical journal demonstrates that while overweight people can lose about a fifth of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing such treatments should be aware of the risk of rapid rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to starting mass within about one and a half years.
Weighing Therapies
The study, which reviewed dozens of trials involving thousands of patients, compared the outcomes of the injectable medications with conventional dieting.
The team point out that people who shed pounds through dieting usually see a less rapid creep back—approximately 0.1 kg a month—after stopping.
Explaining the Fast Rebound
Experts suggest the way of the injections accounts for the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating far more likely."
A Lifelong Issue?
Medical guidelines advise the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the treatment might need to be ongoing.
This opinion is supported by drug manufacturers, who say that the findings "underscore the persistent nature of obesity," comparing it to managing conditions like high blood pressure.
Patient Accounts
People who have come off the medication describe a intense resurgence of cravings.
"I experienced something activating and you're instantly ravenous," said an individual.
This challenge is compounded if patients have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Use
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent fix and long-term success likely depends on integrated lifestyle management.
